🔗 Share this article

Given that the US continues making sweeping revisions to its vaccine guidelines, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccinations during the global health crisis and has concentrated on potential fatalities following Covid immunization in her recent position at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Program

Health officials were set to reveal major revisions to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US out of step with many the global community with no evidence for improved outcomes. The planned update has been postponed until the coming year.

Instead of the director of the vaccine center, Høeg is scheduled to present at the event. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to head the center this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine centers as Høeg and Prasad solidify control at the agency – and it suggests a increased emphasis upon reevaluating long-standing immunizations at the FDA.

Høeg has often pushed for discontinuing some pediatric immunization guidelines in the US in order to be more similar to Denmark's approach, a nation with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – usually the responsibility of Prasad, director of the FDA’s CBER – instead of drug regulation.

Doubts Over Qualifications

Høeg has no obvious background in medication creation, approval processes or leadership, which has been standard for past leaders of the CBER. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for leading the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a sizeable institution. She is not an expert in industry regulation.”

Past commissioners of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who headed CBER have had.”

CDER has an vast portfolio at the agency, she pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and so forth, and each of these need to be supervised,” Dr. Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial management aspect to the job, which oversees in excess of 5,000 staff members. “It’s a enormous leadership role, if you do it right,” the former official added.

Agency Reaction and Contentious Programs

When asked about concerns about Dr. Høeg's credentials and whether this selection indicates greater collaboration among agency officials on vaccines, a press secretary said that the “inquiries are based on flawed premises”.

“Her resume is consistent with the functions of her role,” the representative stated, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg inherits the agency head's recently launched priority voucher program, a controversial one-day therapy clearance system that apparently concerned her predecessors. “How are these medications being picked for this expedited pathway? Who is making the choices?” Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, with the exception of immunizations.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, history, critics observe. She authored a research paper using unverified volunteer-provided data to estimate the frequency of myocarditis after COVID-19 immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are riskier than they are.

Part of her “desired changes” for the incoming government encompassed altering guidelines for new vaccines and halting “non-essential” vaccines, she remarked following the vote on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing young men from receiving COVID-19 vaccinations.

“She is an all-around true believer who starts off with her conclusions and reverse-engineers to retrofit the data in a very deceptive, untruthful fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|